Melanoma Research最新文献_第4页

Interfering with aggregated α-synuclein in advanced melanoma leads to a major upregulation of MHC class II proteins. 干扰晚期黑色素瘤中聚集的α-突触核蛋白会导致MHC II类蛋白质的大量上调。

IF 1.5 4区医学

Melanoma Research Pub Date : 2024-10-01 Epub Date: 2024-07-02 DOI: 10.1097/CMR.0000000000000982

Claudia Fokken, Ivan Silbern, Orr Shomroni, Kuan-Ting Pan, Sergey Ryazanov, Andrei Leonov, Nadine Winkler, Henning Urlaub, Christian Griesinger, Dorothea Becker

{"title":"Interfering with aggregated α-synuclein in advanced melanoma leads to a major upregulation of MHC class II proteins.","authors":"Claudia Fokken, Ivan Silbern, Orr Shomroni, Kuan-Ting Pan, Sergey Ryazanov, Andrei Leonov, Nadine Winkler, Henning Urlaub, Christian Griesinger, Dorothea Becker","doi":"10.1097/CMR.0000000000000982","DOIUrl":"10.1097/CMR.0000000000000982","url":null,"abstract":"Melanoma is the most serious and deadly form of skin cancer and with progression to advanced melanoma, the intrinsically disordered protein α-synuclein is upregulated to high levels. While toxic to dopaminergic neurons in Parkinson's disease, α-synuclein is highly beneficial for primary and metastatic melanoma cells. To gain detailed insights into this exact opposite role of α-synuclein in advanced melanoma, we performed proteomic studies of high-level α-synuclein-expressing human melanoma cell lines that were treated with the diphenyl-pyrazole small-molecule compound anle138b, which binds to and interferes with the oligomeric structure of α-synuclein. We also performed proteomic and transcriptomic studies of human melanoma xenografts that were treated systemically with the anle138b compound. The results reveal that interfering with oligomerized α-synuclein in the melanoma cells in these tumor xenografts led to a substantial upregulation and expression of major histocompatibility complex proteins, which are pertinent to enhancing anti-melanoma immune responses.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"393-407"},"PeriodicalIF":1.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361348/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141476948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hemophagocytic lymphohistiocytosis induced by dabrafenib-trametinib in a patient with metastatic melanoma: a case report and pharmacovigilance analysis. 一名转移性黑色素瘤患者因达拉菲尼-曲美替尼诱发的嗜血细胞淋巴组织细胞增多症：病例报告和药物警戒分析。

IF 1.5 4区医学

Melanoma Research Pub Date : 2024-10-01 Epub Date: 2024-07-22 DOI: 10.1097/CMR.0000000000000992

Joseph B Elmes, Jessica M Davis, Laura W Musselwhite, Zane Chiad, Donald C Moore, Asim Amin

{"title":"Hemophagocytic lymphohistiocytosis induced by dabrafenib-trametinib in a patient with metastatic melanoma: a case report and pharmacovigilance analysis.","authors":"Joseph B Elmes, Jessica M Davis, Laura W Musselwhite, Zane Chiad, Donald C Moore, Asim Amin","doi":"10.1097/CMR.0000000000000992","DOIUrl":"10.1097/CMR.0000000000000992","url":null,"abstract":"Hemophagocytic lymphohistiocytosis (HLH) has been reported rarely with BRAF/MEK inhibitor combinations, including dabrafenib/trametinib. Postmarketing pharmacovigilance analyses evaluating outcomes associated with dabrafenib/trametinib-induced HLH are also lacking. Herein, we report a case of dabrafenib/trametinib-induced HLH in a patient with metastatic melanoma. Recovery of HLH-related symptoms was observed following drug discontinuation, supportive care, and corticosteroids. We also conducted a pharmacovigilance analysis of the USA Food and Drug Administration Adverse Event Reporting System (FAERS) to describe postmarketing cases of HLH with dabrafenib/trametinib exposure. There were 50 reports of HLH with dabrafenib/trametinib in FAERS. Most cases occurred in the setting of melanoma ( n = 39; 78%) and most were reported in Europe ( n = 39; 74%). Hospitalization was the most common outcome ( n = 39; 78%) of this adverse event per FAERS. HLH is a rare complication of dabrafenib/trametinib, and clinicians should be aware and monitor for signs of this potentially serious and life-threatening adverse event.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"465-468"},"PeriodicalIF":1.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141734628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma: Erratum. 使用瘤内 GD2 定向白细胞介素-2 免疫细胞因子和局部放疗激活自发性犬黑色素瘤的免疫排斥反应：勘误。

IF 1.5 4区医学

Melanoma Research Pub Date : 2024-10-01 Epub Date: 2024-08-28 DOI: 10.1097/CMR.0000000000000996

引用次数: 0

High-resolution RNA-sequencing reveals TRIM33::CSDE1 gene fusion in metastasizing vulvar melanoma. 高分辨率 RNA 测序发现转移性外阴黑色素瘤中存在 TRIM33::CSDE1 基因融合。

IF 1.5 4区医学

Melanoma Research Pub Date : 2024-09-18 DOI: 10.1097/CMR.0000000000001005

Magdalena Stawiarz, Mai P Hoang, Artur Kowalik

引用次数: 0

Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma. 使用瘤内 GD2 引导的白细胞介素-2 免疫细胞因子和局部放射治疗激活自发性犬黑色素瘤的免疫排斥反应。

IF 1.5 4区医学

Melanoma Research Pub Date : 2024-08-01 Epub Date: 2024-05-20 DOI: 10.1097/CMR.0000000000000975

Mark R Albertini, Cindy L Zuleger, Erik A Ranheim, Oyewale Shiyanbola, Paul M Sondel, Zachary S Morris, Jens Eickhoff, Michael A Newton, Irene M Ong, Rene Welch Schwartz, Rubi Hayim, Ilene D Kurzman, Michelle Turek, David M Vail

{"title":"Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma.","authors":"Mark R Albertini, Cindy L Zuleger, Erik A Ranheim, Oyewale Shiyanbola, Paul M Sondel, Zachary S Morris, Jens Eickhoff, Michael A Newton, Irene M Ong, Rene Welch Schwartz, Rubi Hayim, Ilene D Kurzman, Michelle Turek, David M Vail","doi":"10.1097/CMR.0000000000000975","DOIUrl":"10.1097/CMR.0000000000000975","url":null,"abstract":"Canine malignant melanoma provides a clinically relevant, large animal parallel patient population to study the GD2-reactive hu14.18-IL-2 immunocytokine as it is similar to human melanoma and expresses GD2. The objectives of this study were to evaluate safety, radiation fractionation, and identify informative biomarkers of an in-situ tumor vaccine involving local radiation therapy plus intratumoral-immunocytokine in melanoma tumor-bearing dogs. Twelve dogs (six dogs/arm) with locally advanced or metastatic melanoma were randomized to receive a single 8 Gy fraction (arm A) or three 8 Gy fractions over 1 week (arm B) to the primary site and regional lymph nodes (when clinically involved) with the single or last fraction 5 days before intratumoral-immunocytokine at 12 mg/m 2 on 3 consecutive days. Serial tumor biopsies were obtained. All 12 dogs completed protocol treatment, and none experienced significant or unexpected adverse events. Evidence of antitumor activity includes one dog with a complete response at day 60, one dog with a partial response at day 60, and four dogs with mixed responses. Histology of serial biopsies shows a variably timed increase in intratumoral lymphocytic inflammation in some dogs. Canine NanoString analyses of serial biopsies identified changes in gene signatures of innate and adaptive cell types versus baseline. There were no significant differences in NanoString results between arm A and arm B. We conclude that intratumoral-immunocytokine in combination with local radiation therapy in canine melanoma is well tolerated and has antitumor activity with the potential to inform clinical development in melanoma patients.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"307-318"},"PeriodicalIF":1.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444423/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141070288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reflectance confocal microscopy versus dermoscopy for the diagnosis of cutaneous melanoma: a head-to-head comparative meta-analysis. 反射共聚焦显微镜与皮肤镜在诊断皮肤黑色素瘤方面的比较：头对头比较荟萃分析。

IF 1.5 4区医学

Melanoma Research Pub Date : 2024-08-01 Epub Date: 2024-06-07 DOI: 10.1097/CMR.0000000000000980

Huasheng Liu, Hong Jiang, Qianqian Shan

{"title":"Reflectance confocal microscopy versus dermoscopy for the diagnosis of cutaneous melanoma: a head-to-head comparative meta-analysis.","authors":"Huasheng Liu, Hong Jiang, Qianqian Shan","doi":"10.1097/CMR.0000000000000980","DOIUrl":"10.1097/CMR.0000000000000980","url":null,"abstract":"This meta-analysis aimed to evaluate the comparative diagnostic performance of reflectance confocal microscopy (RCM) and dermoscopy in detecting cutaneous melanoma patients. An extensive search was conducted in the PubMed and Embase databases to identify available publications up to December 2023. Studies were included if they evaluated the diagnostic performance of RCM and dermoscopy in patients with cutaneous melanoma. The quality of the included studies was assessed using the Quality Assessment of Diagnostic Performance Studies (QUADAS-2) tool. A total of 14 articles involving 2013 patients were included in the meta-analysis. The overall sensitivity of RCM was 0.94 [95% confidence interval (CI), 0.87-0.98], while the overall sensitivity of dermoscopy was 0.84 (95% CI, 0.71-0.95). These results suggested that RCM has a similar level of sensitivity compared with dermoscopy ( P = 0.15). In contrast, the overall specificity of RCM was 0.76 (95% CI, 0.67-0.85), while the overall specificity of dermoscopy was 0.47 (95% CI, 0.31-0.63). The results indicated that RCM appears to have a higher specificity in comparison to dermoscopy ( P < 0.01). Our meta-analysis indicates that RCM demonstrates superior specificity and similar sensitivity to dermoscopy in detecting cutaneous melanoma patients. The high heterogeneity, however, may impact the evidence of the current study, further larger sample prospective research is required to confirm these findings.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"355-365"},"PeriodicalIF":1.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141284229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cytomegalovirus gastritis as a rare adverse event during combined ipilimumab and nivolumab in a patient with melanoma. 一名黑色素瘤患者在联合使用伊匹单抗和尼伐单抗期间出现的罕见不良反应--巨细胞病毒性胃炎。

IF 1.5 4区医学

Melanoma Research Pub Date : 2024-08-01 Epub Date: 2024-05-20 DOI: 10.1097/CMR.0000000000000981

Alice Indini, Rossana Gueli, Michele Cerati, Erika Rijavec, Marco Parravicini, Sabrina Casagrande, Cristina Rovelli, Paolo Antonio Grossi, Francesco Grossi

{"title":"Cytomegalovirus gastritis as a rare adverse event during combined ipilimumab and nivolumab in a patient with melanoma.","authors":"Alice Indini, Rossana Gueli, Michele Cerati, Erika Rijavec, Marco Parravicini, Sabrina Casagrande, Cristina Rovelli, Paolo Antonio Grossi, Francesco Grossi","doi":"10.1097/CMR.0000000000000981","DOIUrl":"10.1097/CMR.0000000000000981","url":null,"abstract":"Immunotherapy has improved survival outcomes of patients with advanced melanoma. Lower gastrointestinal tract immune-related adverse events (irAEs) are common during treatment; however, gastritis is not frequently observed. Herein, we report a case of severe cytomegalovirus (CMV)-related gastritis in a patient treated with ipilimumab and nivolumab for metastatic melanoma. This report presents a 60-year-old woman with stage IV BRAF wild-type melanoma. After the second course of ipilimumab-nivolumab, the patient reported epigastric discomfort after meals, anorexia, and subsequent nausea, vomiting, epigastric pain, and weight loss. Disease staging with PET/CT scan showed very good partial response and diffuse gastroduodenitis. The patient underwent esophagogastroduodenoscopy, showing severe esophageal candidiasis and diffuse hemorrhagic, edematous, and ulcerative mucosa in the whole gastric wall. Biopsies of the gastric wall were obtained. Before receipt of the final pathology report, the patient was empirically started on corticosteroids based on the clinical suspicion of immune-related gastritis, without improvement of symptoms. The hematoxylin-eosin staining demonstrated active gastritis with diffuse nuclear cytopathic viral inclusions in epithelial and interstitial cells; CMV infection was confirmed with immunohistochemical staining. The patient started ganciclovir and fluconazole, with rapid improvement of symptoms. This case presents a rare instance of CMV gastritis in a patient receiving combined anti-PD1 and anti-CTLA4 , in the absence of immune-suppression to manage an irAE. In the case of suggestive symptoms of irAEs, a high index of clinical suspicion is required to rule out concomitant or isolated infective disease. Guidelines for prophylaxis and treatment of these patients are needed, to optimize treatment results.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"386-389"},"PeriodicalIF":1.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141070532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comprehensive clinical imaging, histopathological analysis and liquid biopsy-based surveillance of human uveal melanoma in a prolonged rabbit xenograft model. 在长期兔异种移植模型中对人类葡萄膜黑色素瘤进行全面的临床成像、组织病理学分析和基于液体活检的监测。

IF 1.5 4区医学

Melanoma Research Pub Date : 2024-08-01 Epub Date: 2024-06-07 DOI: 10.1097/CMR.0000000000000964

Prisca Bustamante, Jacqueline Coblentz, Christina Mastromonaco, Emma Youhnovska, Hiroaki Ito, Rita Pinto Proença, Cristina Fonseca, Kyle Dickinson, Emily Marcotte, Myriam MacDonald, Ana-Beatriz Toledo-Dias, Sabrina Bergeron, Alicia Goyeneche, Rafaella Atherino Schmidt Andujar, Thupten Tsering, Alexander Laskaris, Eva Jin, Amélie Nadeau, Tiffany Porraccio, Miguel N Burnier, Julia V Burnier

{"title":"Comprehensive clinical imaging, histopathological analysis and liquid biopsy-based surveillance of human uveal melanoma in a prolonged rabbit xenograft model.","authors":"Prisca Bustamante, Jacqueline Coblentz, Christina Mastromonaco, Emma Youhnovska, Hiroaki Ito, Rita Pinto Proença, Cristina Fonseca, Kyle Dickinson, Emily Marcotte, Myriam MacDonald, Ana-Beatriz Toledo-Dias, Sabrina Bergeron, Alicia Goyeneche, Rafaella Atherino Schmidt Andujar, Thupten Tsering, Alexander Laskaris, Eva Jin, Amélie Nadeau, Tiffany Porraccio, Miguel N Burnier, Julia V Burnier","doi":"10.1097/CMR.0000000000000964","DOIUrl":"10.1097/CMR.0000000000000964","url":null,"abstract":"Uveal melanoma is the most common intraocular tumor in adults. Our group has previously developed a human uveal melanoma animal model; however, adverse effects caused by the immunosuppressive agent, cyclosporine A, prevented animals from surviving more than 12 weeks. In this study, we tested multiple cyclosporine A doses over an extended disease course up to 20 weeks, providing complete clinical imaging of intraocular tumors, histopathological analysis and liquid biopsy biomarker analysis. Twenty albino rabbits were divided into four groups with different daily cyclosporine A schedules (0-10 mg/kg) and inoculated with human uveal melanoma cell lines, 92.1 or MP41, into the suprachoroidal space. Rabbits were monitored with fundoscopy, ultrasound and optical coherence tomography. Intraocular tumors (macroscopic or microscopic) were detected in all study animals. Tumor size and growth were correlated to cyclosporine A dose, with tumors regressing when cyclosporine A was arrested. All tumors expressed HMB-45 and MelanA; however, tumor size, pigmentation and cell morphology differed in 92.1 vs. MP41 tumors. Finally, across all groups, circulating tumor DNA from plasma and aqueous humor was detected earlier than tumor detection by imaging and correlated to tumor growth. In conclusion, using three clinically relevant imaging modalities (fundoscopy, ultrasonography and optical coherence tomography) and liquid biopsy, we were successfully able to monitor tumor progression in our rabbit xenograft model of human uveal melanoma.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"285-295"},"PeriodicalIF":1.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141284228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relationships between survival and real-world recurrence-free survival or distant metastasis-free survival among patients with completely resected stage IIB or IIC melanoma. 完全切除的 IIB 期或 IIC 期黑色素瘤患者的生存期与实际无复发生存期或无远处转移生存期之间的关系。

IF 1.5 4区医学

Melanoma Research Pub Date : 2024-08-01 Epub Date: 2024-05-27 DOI: 10.1097/CMR.0000000000000962

Wolfram Samlowski, Michelle A Silver, Andriana Hohlbauch, Shujing Zhang, Mizuho Fukunaga-Kalabis, Clemens Krepler, Yunfei Wang, Ila Sruti, Ruixuan Jiang

{"title":"Relationships between survival and real-world recurrence-free survival or distant metastasis-free survival among patients with completely resected stage IIB or IIC melanoma.","authors":"Wolfram Samlowski, Michelle A Silver, Andriana Hohlbauch, Shujing Zhang, Mizuho Fukunaga-Kalabis, Clemens Krepler, Yunfei Wang, Ila Sruti, Ruixuan Jiang","doi":"10.1097/CMR.0000000000000962","DOIUrl":"10.1097/CMR.0000000000000962","url":null,"abstract":"Long follow-up time is needed for overall survival (OS) data to mature for early-stage melanoma. This retrospective study aimed to describe the relationships between OS and two intermediate endpoints - real-world recurrence-free survival (rwRFS) and real-world distant metastasis-free survival (rwDMFS) - for patients with stage IIB or IIC melanoma that was completely resected from 1 January 2008 to 31 December 2017, with follow-up to 31 December 2020. We used three different approaches to describe the relationships: estimates of correlation using Kendall τ rank correlation; comparisons of all-cause survival with/without recurrence or distant metastasis using adjusted Cox proportional hazard models; and landmark analyses of all-cause survival stratified by recurrence status at 1-5 years. During a 39-month median follow-up from surgical resection, 223/567 patients (39%) experienced recurrence, among whom 171/567 patients (30%) developed distant metastasis. Median OS from surgical resection was 117.6 months [95% confidence interval (CI), 104.7-not reached], median rwRFS was 49.8 months (95% CI, 39.6-61.0), and median rwDMFS was 70.9 months (95% CI, 58.4-89.1). We observed strong correlations between rwRFS and OS, and between rwDMFS and OS (Kendall τ of 0.73 and 0.82, respectively). Risk of death was significantly greater after recurrence (all-cause survival adjusted hazard ratio [HR], 7.48; 95% CI, 4.55-12.29) or distant metastasis (adjusted HR, 11.00; 95% CI, 6.92-17.49). Risk of death remained significantly elevated with recurrence or distant metastasis by landmark years 1, 3, and 5 after surgical resection. These findings support the use of recurrence/rwRFS and distant metastasis/rwDMFS as surrogate endpoints for OS after complete resection of stage IIB or IIC melanoma.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"326-334"},"PeriodicalIF":1.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141180005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A retrospective study of clinicopathological and prognostic characteristics in 177 Chinese patients with acral melanoma: heterogeneity based on tumor site. 177 例中国尖锐湿疣黑色素瘤患者临床病理和预后特征的回顾性研究：基于肿瘤部位的异质性。

IF 1.5 4区医学

Melanoma Research Pub Date : 2024-08-01 Epub Date: 2024-06-26 DOI: 10.1097/CMR.0000000000000976

Shiwen Wang, Hongyu Zhou, Yangyang Ma, Sha Jin, Yige Zhao, Panpan Wang, Chenyu Tang, Mengyan Zhu, Jiaqi Wang, Ping Wang

引用次数: 0